Humana Inc

UnitedHealth Group is shifting its Medicare Advantage strategy to prioritize profitability over membership expansion, expecting 2026 enrollment to decline by approximately 1.1 million members due to targeted exits from unprofitable plans. Medicare margins are now expected to finish the year above 3%, reflecting tighter benefit design, pricing actions, and a more favorable membership mix, while the company expects Medicare medical cost trends to come below the initial estimate of near 10%. UnitedHealth's consolidated medical care ratio improved to 86.7% in the second quarter from 89.4% a year ago, and the company raised its 2026 adjusted EPS outlook to $19.50-$20. The Zacks Consensus Estimate for UnitedHealth's 2026 earnings is pegged at $19.69 per share, implying 20.4% growth from the year-ago period, and the stock currently carries a Zacks Rank #1 (Strong Buy).

Nearly 3 million older Americans face forced disenrollment from their Medicare Advantage plans this year as major insurers exit markets to protect profits. An analysis by Johns Hopkins Bloomberg School of Public Health researchers found one in 10 Medicare Advantage policyholders are losing their plans, up from a 6.9% disenrollment rate in 2025 and an average of 1% between 2018 and 2024. Humana announced it will exit multiple markets in 2027 for the second consecutive year, impacting 600,000 members, while Clear Spring Health shut down its Medicare Advantage operations effective June 1 and Presbyterian Health Plan will exit most markets in 2027 affecting about 30,000 policyholders. Insurers cite lower federal reimbursement rates and rising medical costs, with UnitedHealth and Humana together accounting for nearly half of all Medicare Advantage enrollment nationwide.

Humana lowered its full-year 2026 GAAP EPS guidance to at least $6.52 from at least $8.36, even as it reported second-quarter revenue of $40,867 million and net income of $694 million. The company also confirmed completion of a $276.13 million share repurchase program and announced two new board appointments, Paul Smith and Frederick Crawford. The guidance cut signals a more cautious profitability outlook amid medical cost and Stars-related headwinds, while the quarterly beat and stable revenue trends indicate the core Medicare Advantage and CenterWell franchise remains intact.

The healthcare sector gained about 2.45% in July, outperforming the broader S&P 500 which slipped around 0.12%. Regeneron Pharmaceuticals was the biggest winner, climbing 22.08%, followed by DexCom which gained 21.19% after its Q2 earnings beat and raised full-year guidance, and Baxter International which advanced 20.61%. Moderna was the biggest detractor, dropping 24.39%, while Intuitive Surgical fell 12.19% and managed-care insurers Humana, Elevance Health, and Centene also finished among the weakest performers. Earnings-driven gains in pharmaceuticals and medtech contrasted with weakness in managed-care insurers and vaccine makers.

Humana cut its full-year earnings outlook on Wednesday as lower Medicare Advantage Star Ratings reduced the quality bonuses it receives from the federal government. The health insurer revised its full-year GAAP earnings target to a minimum of $6.52 per share, down from its earlier projection of at least $8.36 per share, while leaving its adjusted forecast intact at a minimum of $9 per share. A significant decline in the number of Humana's plans rated four stars or higher has weighed on its 2026 bonus payments from the Centers for Medicare and Medicaid Services. Second-quarter profit rose to $694 million, or $5.73 per share, from $545 million, or $4.51 per share, a year earlier, with total revenue up 26% to $40.87 billion. On an adjusted basis, the company earned $7.61 per share, beating the Wall Street Journal analyst consensus of $7.26. Humana also reaffirmed its expectation that individual Medicare Advantage enrollment will expand by roughly 25% compared with 2025, and its stock fell about 9% in premarket trading.

A Trump administration decision to end a Medicare Part D subsidy program means that three out of four enrollees will see higher plan premiums in 2027. About 45% of enrollees will see an $11 to $20 monthly increase, while another 30% will pay $10 or under more per month, according to a report in The Wall Street Journal. An administration official told the newspaper that the subsidy provided an incentive for health insurers to boost rates as the federal government would foot the additional amount. The subsidy provided approximately $3.6 billion in support in 2026, according to the Government Accountability Office. The top Medicare Part D insurers include Centene, Humana, and UnitedHealth Group.

Pzena Investment Management's Focused Value Strategy returned negative 4.7% net in the first quarter of 2026, underperforming the Russell 1000 Value Index's 2.1% gain. The portfolio was weighed down by the health care, financials, and technology sectors, with Medicare Advantage insurer Humana Inc. emerging as the largest individual detractor. Humana's shares fell after the Centers for Medicare and Medicaid Services proposed a disappointing preliminary Medicare Advantage rate update for 2027, and management's projection of rapid membership growth in 2026 raised investor concerns about overly rich plan benefit design relative to peers. Pzena views these risks as more timing-related than thesis-changing and added to its Humana position on weakness. Humana closed at $360.72 per share on June 22, 2026, with a market capitalization of $43.31 billion, and was held by 61 hedge funds at quarter-end, up from 53 in the prior quarter.

CVS Health is under scrutiny after a New York Times report highlighted that it and other major Medicare Advantage insurers frequently denied necessary rehabilitation care to older Americans. The article, citing two federal reports, stated that top providers rejected roughly 13% of patient requests for skilled nursing facility admissions, with denial rates reaching 40% for existing nursing home residents. A CVS spokesman said the company evaluates requests promptly and provides a transparent appeals process. Separately, Mizuho raised its price target on CVS to $115 from $110 on June 8, maintaining an Outperform rating, citing a more stable policy environment.

UnitedHealth Group appears better positioned than Humana among healthcare leaders, according to a Zacks Investment Research analysis. UnitedHealth benefits from a diversified platform spanning insurance, health services, and technology, while Humana remains more focused on Medicare. UnitedHealth trades at 20.57 times forward earnings with a 2.3% dividend yield, compared to Humana's 30.47 times multiple and 1% yield. Consensus estimates project UnitedHealth's 2026 earnings will rise 12.1%, whereas Humana's are expected to drop 47.4%. Both stocks carry a Zacks Rank #3, or Hold.

UBS analysts say hospitals could build a more durable competitive advantage from artificial intelligence than health insurers, even as AI becomes a core operating layer across healthcare. Analyst A.J. Rice notes that while managed-care companies like UnitedHealth Group, Elevance Health, Humana, Cigna, and Centene are deploying AI for claims processing, prior authorization, and customer service, those efficiency gains are highly replicable and likely to be competed away through pricing or benefit enhancements. In contrast, large for-profit hospital operators such as HCA Healthcare, Tenet Healthcare, and Universal Health Services are using AI for revenue cycle management, denial appeals, and staffing optimization, and may maintain a multiyear lead over slower-moving nonprofit systems. UBS highlights that Universal Health Services generated approximately $50 million in annualized additional revenue from an AI coding platform, while HCA is using AI to fight claim denials and optimize nurse staffing with a Palantir-built platform. The report concludes that AI will improve profitability unevenly, with hospitals better positioned to retain gains and expand margins over time.